Tdam USA Inc. increased its position in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 11.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 134,529 shares of the medical instruments supplier’s stock after buying an additional 14,229 shares during the period. Tdam USA Inc. owned approximately 0.06% of DENTSPLY SIRONA worth $8,685,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of XRAY. Korea Investment CORP raised its position in shares of DENTSPLY SIRONA by 139.9% in the second quarter. Korea Investment CORP now owns 2,145 shares of the medical instruments supplier’s stock valued at $139,000 after buying an additional 1,251 shares during the last quarter. First Manhattan Co. raised its position in shares of DENTSPLY SIRONA by 43.0% in the second quarter. First Manhattan Co. now owns 13,986 shares of the medical instruments supplier’s stock valued at $906,000 after buying an additional 4,208 shares during the last quarter. Emerald Advisers Inc. PA raised its position in shares of DENTSPLY SIRONA by 16.9% in the second quarter. Emerald Advisers Inc. PA now owns 24,423 shares of the medical instruments supplier’s stock valued at $1,584,000 after buying an additional 3,524 shares during the last quarter. S&CO Inc. raised its position in shares of DENTSPLY SIRONA by 102.8% in the second quarter. S&CO Inc. now owns 15,564 shares of the medical instruments supplier’s stock valued at $1,009,000 after buying an additional 7,890 shares during the last quarter. Finally, Grandfield & Dodd LLC raised its position in shares of DENTSPLY SIRONA by 1.6% in the second quarter. Grandfield & Dodd LLC now owns 231,969 shares of the medical instruments supplier’s stock valued at $15,041,000 after buying an additional 3,573 shares during the last quarter. Institutional investors own 95.17% of the company’s stock.

Shares of DENTSPLY SIRONA Inc. (XRAY) opened at 61.59 on Monday. The firm has a market capitalization of $14.12 billion, a PE ratio of 39.63 and a beta of 1.26. DENTSPLY SIRONA Inc. has a 52 week low of $55.00 and a 52 week high of $65.68. The stock has a 50 day moving average price of $63.88 and a 200 day moving average price of $62.25.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Tuesday, May 9th. The medical instruments supplier reported $0.49 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.50 by $0.01. The business had revenue of $900.50 million for the quarter, compared to analyst estimates of $916.55 million. DENTSPLY SIRONA had a net margin of 9.42% and a return on equity of 7.37%. The business’s revenue was up 16.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.69 EPS. Equities analysts forecast that DENTSPLY SIRONA Inc. will post $2.84 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 13th. Investors of record on Friday, September 29th will be issued a dividend of $0.0875 per share. The ex-dividend date is Thursday, September 28th. This represents a $0.35 annualized dividend and a dividend yield of 0.57%. DENTSPLY SIRONA’s payout ratio is 22.58%.

ILLEGAL ACTIVITY WARNING: This story was first reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.dailypolitical.com/2017/08/07/tdam-usa-inc-has-8-69-million-position-in-dentsply-sirona-inc-nasdaqxray.html.

Several research analysts recently weighed in on the company. BidaskClub lowered DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Zacks Investment Research upgraded DENTSPLY SIRONA from a “hold” rating to a “buy” rating and set a $72.00 price target on the stock in a research note on Thursday, July 13th. Credit Suisse Group restated an “outperform” rating and set a $75.00 price target (up from $67.00) on shares of DENTSPLY SIRONA in a research note on Thursday, July 13th. HC Wainwright assumed coverage on DENTSPLY SIRONA in a research note on Tuesday, July 11th. They set a “buy” rating and a $74.00 price target on the stock. Finally, Cleveland Research upgraded DENTSPLY SIRONA from a “neutral” rating to a “buy” rating in a research note on Tuesday, May 23rd. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company. DENTSPLY SIRONA presently has a consensus rating of “Buy” and a consensus target price of $67.92.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc. (NASDAQ:XRAY).

Institutional Ownership by Quarter for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.